SIStockInvestingSI.com

NYSE · JNJ · Drug Manufacturers - General

Johnson & Johnson (JNJ) stock analysis

$257.78−0.61%Data as of Oct 21, 2026
  • JNJ lost 4.2% over the past month versus 0.0% for the S&P 500, ranking 390th of 497 S&P 500 stocks.
  • Over 12 months it returned +34.6%, 18.8 points ahead of the S&P 500, and trades 7.4% below its 52-week high.
  • In the last 30 days 0 analysts raised earnings estimates and 2 cut; forward EPS moved −4.3% (−9.4% over 90 days).
  • It sits in the Large pharma segment of the Healthcare Value Chain, where the 1-month median return is −0.7%.
  • The daily chart reads Trend transition · Unresolved structure (since Oct 1, 2026).
Market cap$621.2B
12-month return+34.6%
Forward P/E21.4×
Mean target vs price+8.5%

One-year price with 50- and 200-day averages

Open in Hub
172204237269JanAprJulOct
257.7850-day200-day

Performance vs the market

Total price return against the S&P 500 (SPY) and the median of US stocks in the same sector.

JNJ−4.2%
Sector median−8.7%
S&P 5000.0%
JNJ−0.6%
Sector median−5.4%
S&P 500+4.7%
JNJ+14.0%
Sector median−1.5%
S&P 500+8.7%
JNJ+34.6%
Sector median+1.7%
S&P 500+15.8%
1-month rank in the S&P 500390 / 497
3-month rank in its sector · Healthcare316 / 720

Chart structure

Read by our daily-bar structure engine from swing highs, swing lows and moving averages.

Trend transition · Unresolved structureAwaiting confirmation

Holding since Oct 1, 2026

  • Close below EMA20 below EMA50
  • EMA50 fell over the last ten sessions
  • Intermediate and long-term directions differ
  • Neither a stable trend nor a range is confirmed
This pattern on this stock

80 occurrences in 10 years. The median move over the next 20 sessions was +0.4%, positive 51% of the time, against +0.6% for any day in the same period.

Reference zone, stop and targets for this structureSee the trade plan in Hub ↗

Analyst earnings revisions

Changes to the consensus forward-EPS estimate. Rising estimates mean analysts see more profit ahead.

Forward EPS$11.62
30-day change−4.3%
90-day change−9.4%
Mean target$279.82 +8.5%
Raised (30d) 0Cut (30d) 2

22 analysts cover the stock

Fundamental shape vs peers

Six dimensions on fixed scales. The filled shape is the company; the outline is the peer average.

Open the full Radar with every ratio
ValuationRevisionsMomentumGrowthCashProfit

Behind peersGrowth, Revisions

PeersLLY · ABBV · MRK · NVS

Where it sits in the supply chain

Healthcare Value Chain · Drugs & devices

Explore the full chain map in Hub
Supplied by
Life-science tools & bioprocessing+6.0%
TMO+5.4%1 monthDHR+6.0%1 monthA+6.4%1 month
Clinical research outsourcing+8.0%
IQV+2.4%1 monthFTRE+17.8%1 monthICLR+10.9%1 monthMEDP+5.1%1 month
Its segment
Large pharma−0.7%
JNJ−4.2%1 monthMRK−0.7%1 monthABBV+7.4%1 monthPFE+6.9%1 monthBMY−0.8%1 month

Oncology, immunology and vaccines, facing patent expiries and US price negotiation; policy news often moves the group together.

Sells into
Drug distribution+13.9%
MCK+13.9%1 monthCOR+8.3%1 monthCAH+16.2%1 month
Government programs & policy

Figures are each company's 1-month return; the segment shows its median · Doubler daily batch · company chain maps

Risk profile

Max drawdown, 12M−11.0%
Volatility, 60D23.0%
From 52-week high−7.4%
From 52-week low+40.2%
Trailing P/E29.9×
Forward P/E21.4×

Themes

  • Gene/Cell Therapy3M rank 52 / 99
MRKMerckABBVAbbViePFEPfizerBMYBristol Myers SquibbTMOThermo Fisher ScientificDHRDanaherAAgilent Technologies, Inc.IQVIQVIA Holdings, Inc.

Track this stock every day

Hub adds the daily brief, StockFlow factor flow, trade plans and alerts for your watchlist.

Open in Hub ↗